Table 2.
Severe Toxicities Causing Physicians to Interrupt, Dose Reduce, Discontinue, or Switch a Patient’s Tyrosine Kinase Inhibitor Therapy (Question 29)a
| Toxicity | % Interrupt | % Dose Reduce | % Discontinue | % Switch |
|---|---|---|---|---|
| Nausea/Vomiting | 30.8 | 34.3 | 5.1 | 9.1 |
| Upset Stomach | 20.1 | 29.8 | 3.0 | 5.9 |
| Diarrhea | 25.2 | 36.3 | 5.1 | 8.3 |
| Rash | 26.2 | 29.2 | 6.7 | 10.5 |
| Neutropenia | 32.7 | 47.7 | 7.3 | 8.9 |
| Thrombocytopenia | 29.0 | 45.4 | 8.5 | 8.3 |
| Anemia | 19.5 | 36.9 | 4.7 | 4.5 |
| Muscle Cramps | 20.7 | 27.6 | 3.2 | 6.9 |
| Liver Dysfunction | 22.9 | 31.4 | 15.4 | 16.6 |
| Fluid Retention | 20.1 | 33.9 | 7.9 | 14.0 |
| Periorbital Edema | 17.6 | 27.8 | 5.1 | 8.3 |
| Pleural Effusion | 22.7 | 24.5 | 21.7 | 27.6 |
| Pericardial Effusion or Pericarditis | 17.0 | 16.6 | 19.1 | 24.9 |
| Weight Gain | 16.0 | 23.1 | 3.4 | 6.9 |
| Congestive Heart Failure | 15.4 | 16.0 | 21.1 | 26.4 |
| Fatigue | 19.1 | 33.5 | 3.2 | 9.7 |
| Bone Aches | 17.0 | 25.8 | 2.8 | 5.7 |
a
Multiple answers were allowed.